

Corrigendum

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study

Jurij Hanzel MD,^{*,†} Erwin Dreesen PharmD, PhD,^{‡,§} Séverine Vermeire MD, PhD,[¶] Mark Löwenberg MD, PhD,[†] Frank Hoentjen MD, PhD,[¶] Peter Bossuyt MD, PhD,^{**} Esmé Clasquin MSc,[†] Filip J. Baert MD, PhD,^{††} Geert R. D'Haens MD, PhD,[†] and Ron Mathôt PharmD, PhD^{**}

From the *Faculty of Medicine, University of Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia;

[†]Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands;

[‡]Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium;

[§]Department of Pharmacy, Uppsala University, Uppsala, Sweden;

[¶]Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium;

[¶]Department of Gastroenterology and Hepatology, Radboud UMC, Nijmegen, the Netherlands;

^{**}Imelda GI Clinical Research Centre, Imelda General Hospital, Bonheiden, Belgium;

^{††}Division of Gastroenterology, AZ Delta, Roeselare, Belgium;

^{**}Department of Hospital Pharmacy—Clinical Pharmacology, Amsterdam UMC, Amsterdam, the Netherlands

Address correspondence to: Jurij Hanzel, MD, Faculty of Medicine, University of Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia (jurij.hanzel@gmail.com).

In the originally published version of this manuscript, reference 36 incorrectly read “Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. *Gastroenterology*. 2020;158:2139–2149.e14”. It should have read “Sandborn

WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. *Gastroenterology*. 2020;158(3):562-572 e512.” This has now been corrected online.